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Abstract
Background: The association between circulating microRNA-122 (miR-122) and histopathological features of
nonalcoholic fatty liver disease (NAFLD) remains unclear.
Methods: The association of serum miR-122 levels with histopathological features of NAFLD (steatosis, ballooning,
lobular inflammation, and stage, as histological components of nonalcoholic steatohepatitis) was examined in serial
liver biopsies from 36 hepatocellular carcinoma (HCC)-free Japanese patients with histopathologically-proven NAFLD.
The median interval between first and second liver biopsies was 4.6 years.
Results: In patients who showed improvement of histopathological scores (steatosis, ballooning, and stage), serum
miR-122 levels were significantly lower at second biopsy than first biopsy. In patients who showed no improvement,
the changes at second biopsy were not different from those at first biopsy. There were significant and strong
associations between serum miR-122 ratio (ratio of level at second biopsy to that at first biopsy) and changes in
histopathological scores (of steatosis, lobular inflammation, and stage). There were also significant and strong
associations between serum miR-122 ratio and changes in other clinical parameters, including aspartate
aminotransferase and alanine aminotransferase.
Conclusions: Longitudinal examination of serial liver biopsies showed the association of serum miR-122 with
histopathological features of HCC-free NAFLD patients.
Keywords: Nonalcoholic fatty liver disease, Nonalcoholic steatohepatitis, Serial liver biopsy, Longitudinal observation,
microRNA-122, Circulating
Background
Non-alcoholic fatty liver disease (NAFLD) is currently
the most common liver disease worldwide across differ-
ent ethnicities [1–7], and associated with serious
healthcare issues. NAFLD includes a wide spectrum of
liver pathologies ranging from non-alcoholic fatty liver,
which is usually benign, to non-alcoholic steatohepatitis
(NASH), which may lead to liver cirrhosis, hepatocellular
carcinoma (HCC), and liver failure without excessive alco-
hol intake [8]. Treatment with vitamin E and Farnesoid X
nuclear receptor ligand obeticholic acid is reported to
improve the histological features of NAFLD [9, 10].
NASH can only be diagnosed by the presence of histo-
pathological components, such as steatosis, lobular in-
flammation, ballooning, and fibrosis. Hence, there is a
need for non-invasive surrogate markers of histopatho-
logical features. The severity and progression of NAFLD
is influenced by various factors, including environmental
factors, and genetic and epigenetic variations [11–14].
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Recent studies have explored the utility of circulating
microRNA for assessment of NAFLD. Several reports
indicated that serum levels of several microRNAs were
increased in patients with NAFLD, and that serum
microRNA-122 (miR-122) levels correlated with histo-
pathological disease severity [15–18]. Based on serial
follow-up of rats with experimentally-induced NAFLD,
Yamada et al. [19] concluded that serum miR-122 level
was indeed useful for the assessment of early NAFLD
and could be superior to traditional clinical markers that
are often used to monitor liver diseases. Takaki et al. [20]
examined HCC tissues of mice with experimentally-
induced NASH and concluded that silencing of miR-122
is an early event during hepatocarcinogenesis from NASH,
and that miR-122 is potentially suitable for evaluation of
the risk of HCC in patients with NASH. In a cross-
sectional study based on large number of patients with
histopathologically-confirmed NAFLD, we recently identi-
fied the absence of HCC and/or histopathological severity
of NASH as independent predictors of high serum levels
of miR-122. In another study, we followed three HCC pa-
tients with histopathologically-confirmed NAFLD and
showed a decline in serum miR-122 levels before the pro-
gression of fibrosis stage [21]. However, there is no infor-
mation at present on the longitudinal effect of serum
miR-122 on histopathological features of NAFLD.
The aim of this single-center retrospective cohort
study was to determine the long-term effects of serum
miR-122 on histopathological features of NAFLD in pa-
tients free of HCC.
Methods
Patients
A total of 321 Japanese patients were diagnosed with
NAFLD based on histopathological examination of liver
biopsies between 1980 and 2016 at Toranomon Hospital.
Of these, 39 patients underwent at least two liver biop-
sies and were evaluated in detail clinically over time.
The need for repeated liver biopsies was determined by
the attending physician. Of the 39 patients, 36 did not
develop HCC during the period from the first to the sec-
ond biopsy (median: 4.6 years, range: 0.5-19.0 years).
The association between serum miR-122 and histopatho-
logical features of NAFLD in these 36 patients free of
HCC was evaluated longitudinally.
NAFLD was diagnosed based on liver histopathological
findings of steatosis in ≥5% of hepatocytes and the ex-
clusion of other liver diseases (such as primary biliary
cirrhosis, autoimmune hepatitis, drug induced liver dis-
ease, viral hepatitis, hemochromatosis, biliary obstruc-
tion, α-1-antitrypsin deficiency-associated liver disease,
and Wilson disease). None of the 36 patients consumed
more than 20 g/day alcohol.
The study protocol was in compliance with the Good
Clinical Practice Guidelines and the 1975 Declaration of
Helsinki, and was approved by the institutional review
board of Toranomon Hospital. All patients provided
written informed consent at the time of liver histopatho-
logical diagnosis.
Liver histopathology
Liver specimens were obtained using a 14-gauge modified
Vim Silverman needle (Tohoku University style, Kakinuma
Factory, Tokyo, Japan), a 16-gauge core tissue biopsy nee-
dle (Bard Peripheral Vascular Inc., Tempe, AZ) or surgical
resection. The biopsy tissue sample was fixed in 10% for-
malin, and sections were stained with hematoxylin-eosin,
Masson trichrome, silver impregnation, and periodic acid-
Schiff after diastase digestion. The specimens were evalu-
ated by four pathologists (K.K., F.K., T.F., and T.F.) who
were blinded to the clinical findings. An adequate liver bi-
opsy sample was defined as a specimen more than 1.5 cm
long tissue strip and/or containing more than 11 portal
tracts. Specimens with steatosis of <5%, 5–33%, 34–66%,
and >66% were scored as steatosis grade 0, 1, 2, and 3, re-
spectively. Lobular inflammation of no foci, <2 foci, 2-4
foci, and >4 foci per 200× field was scored as 0, 1, 2, and 3,
respectively. Hepatocyte ballooning of none, few cells, and
many cells was scored as 0, 1, and 2, respectively. NAFLD
activity score represented the sum of steatosis, lobular in-
flammation, and hepatocyte ballooning scores (range, 0–8
points; 5–8 points as definition of NASH). Fibrosis
stage of none, zone 3 perisinusoidal fibrosis (stage 1),
zone 3 perisinusoidal fibrosis with portal fibrosis (stage 2),
zone 3 perisinusoidal fibrosis and portal fibrosis with
bridging fibrosis (stage 3), and cirrhosis (stage 4) was
scored as 0, 1, 2, 3, and 4, respectively [22, 23]. Patients
were also classified into four categories by histopathology
according to the classification of Matteoni et al. [24] as
follows; type 1: fatty liver alone, type 2: fat accumulation
and lobular inflammation, type 3: fat accumulation and
ballooning degeneration, type 4: fat accumulation, bal-
looning degeneration, and either Mallory-Denk body or
fibrosis (type 3 or 4 as definition of NASH).
A decrease of one point or more in the histopathological
score at the time of second biopsy (relative to the first
biopsy) was classified as "improvement", no change as
“no change”, while an increase of one point or more
was termed “progression”. Changes in histopathological
score (Δchange) represented the score at the second bi-
opsy minus that at the first biopsy.
Clinical parameters
Table 1 summarizes the clinical features of 36 patients of
NAFLD free of HCC recorded at the time of first and sec-
ond biopsies. The normal ranges of aspartate aminotrans-
ferase (AST) and alanine aminotransferase (ALT) at our
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hospital are 13-33 IU/l and 8-42 IU/l for males and 6-
27 IU/l for females, respectively. Obesity was defined as
body mass index (BMI) of more than 25.0 kg/m2. Non
high-density lipoprotein cholesterol was defined as total
cholesterol minus high-density lipoprotein cholesterol.
Changes in clinical parameters or laboratory tests repre-
sented the value at second biopsy minus that at first biopsy.
Measurement of serum miR-122
Serum samples were obtained at least twice a year after
the time of histopathological diagnosis of NAFLD. The
sample was frozen at –80 °C within 4 h of collection
and thawed just before analysis. Circulating microRNA
was extracted from 200 μl of serum samples using the
QIAGEN miRNeasy serum-plasma kit (Qiagen K.K.,
Tokyo) according to the instructions provided by the
manufacturer. RNA was reverse transcribed using TaqMan
MicroRNA Reverse Transcription kit (Life Technologies
Japan, Tokyo). Caenorhabditis elegans miR-39 (cel-miR-39)
was spiked in each sample as a control for extraction and
amplification steps. Table 2 provides details of the protocol
used for measurement of serum miR-122, as described pre-
viously [25]. Serum miR-122 was amplified using primers
and probes provided by Applied Biosystems (Foster
City, CA) by the TaqMan MicroRNA assay, according
to the instructions provided by the manufacturer. The
relative expression of serum miR-122 was calculated using
the comparative cycle threshold (CT) method (2-ΔΔCT)
[26, 27] with spiked cel-miR-39 as normalized internal
control. The miRNA expression levels were expressed
relative to the levels of serum miR-122 measured in 286
clinical samples [21]. Serum miR-122 ratio represented
serum miR-122 level at second biopsy to that at first
biopsy.
Statistical analysis
Wilcoxon test was used for comparison of paired samples.
Correlation analysis was evaluated by the Spearman rank
correlation test. All p values less than 0.05 by the two-
tailed test were considered significant. Statistical analyses




Table 3 summarizes the distribution of histopathological
scores at the time of first and second liver biopsies. The
steatosis score indicated progression, no change, and im-
provement in 33.3%, 55.6%, and 11.1% of the 36 patients,
respectively (Table 3), with a median change per year for
the entire group of 0.000/year (range, -2.393 to 0.778/
year). The ballooning score indicated progression, no
change, and improvement in 13.9%, 63.9%, and 22.2% of
the patients, respectively (Table 3), with a median change
per year of 0.000/year (range, -2.393 to 0.178/year). Analysis
of the lobular inflammation score indicated that 27.8%,
33.3%, and 38.9% of the patients showed progression, no
change, and improvement, respectively (Table 3), with a
median change per year of 0.000/year (range, -0.1.429 to
1.164/year). The stage scores indicated progression, no
change, and improvement in 27.8%, 52.8%, and 19.4% of
the patients, respectively (Table 3), with a median change
per year of 0.000/year (range, -0.714 to 0.516/year).
Table 1 Clinical characteristics at the time of the first and second
liver biopsies, of 36 patients with NAFLD free of hepatocellular
carcinoma
First biopsy Second biopsy
Demographic data
Number of patients 36 36
Gender (Male/Female) 20/16 20/16
Histological findings
Steatosis (0/1/2/3) 0/8/20/8 1/15/15/5
Lobular inflammation (0/1/2/3) 4/14/13/5 2/20/14/0
Ballooning (0/1/2) 2/21/13 4/23/9
Stage (0/1/2/3/4) 5/13/6/11/1 2/16/5/12/1
Matteoni classification (type 1/2/3/4) 1/1/3/31 0/1/1/33
NAFLD activity score (≤2/3, 4/≥5) 2/12/22 4/16/16
Clinical parameters
Age (years) 49 (24-69) 59 (26-70)
Body mass index (kg/m2) 25.6 (20.5-36.5) 25.5 (19.1-33.6)
Serum aspartate aminotransferase
(IU/l)
61 (19-152) 37 (14-132)
Serum alanine aminotransferase
(IU/l)
104 (28-303) 49 (8-304)
Gamma-glutamyl transpeptidase
(IU/l)
65 (17-505) 43 (9-359)
Serum albumin (g/dl) 4.1 (3.4-4.9) 4.0 (2.8-4.5)
Platelet count (×103/mm3) 210 (117-389) 207 (111-296)
Fasting plasma glucose (mg/dl) 94 (65-142) 106 (73-278)
Uric acid (mg/dl) 6.0 (1.8-9.5) 5.9 (1.5-9.2)
Total cholesterol (mg/dl) 209 (130-290) 202 (131-270)
Triglycerides (mg/dl) 137 (62-254) 131 (54-295)
High-density lipoprotein cholesterol
(mg/dl)
44 (29-85) 45 (27-73)
Low-density lipoprotein cholesterol
(mg/dl)
129 (66-205) 123 (64-175)
Non high-density lipoprotein
cholesterol (mg/dl)
162 (95-228) 150 (95-219)
Serum ferritin (μg/l) 265 (<10-1,472) 202 (13-1,018)
Hyaluronic acid (μg/l) 34 (8-561) 30 (0-222)
Serum miR-122 (fold change) 1.03 (0.13-7.63) 0.66 (0.03-7.65)
Data are number of patients or median (range) values
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Association of serum miR-122 level with histopathological
features
Figure 1 shows serum miR-122 levels at the time of the
first and second liver biopsies, according to histopatho-
logical features. In 12 patients who showed improvement
in steatosis scores, serum miR-122 levels were signifi-
cantly lower at the second biopsy compared with first bi-
opsy (P = 0.002, Fig. 1a). In 5 patients who showed
progression of ballooning scores, serum miR-122 levels
were significantly lower at second biopsy than at first bi-
opsy (P = 0.043). In 8 patients who showed improvement
of ballooning scores, serum miR-122 levels were signifi-
cantly lower at second biopsy than at first biopsy (P =
0.012, Fig. 1b). In 7 patients who showed improvement
of stage scores, serum miR-122 levels were significantly
lower at second biopsy compared with at first biopsy
(P = 0.018, Fig. 1d).
Association of changes in clinical parameters with
histopathological scores
Table 4 shows the association of changes in clinical param-
eters with histopathological scores. There was significant
and strong association (r ≥ 0.5) between ΔSteatosis and
serum miR-122 ratio (r = 0.5, P = 0.001). There were also
significant and strong associations between ΔLobular in-
flammation and ΔBMI (r = 0.6, P < 0.001), ΔAST (r = 0.6,
Table 2 Protocol used for analysis of serum miR-122
(A) Preparation of the RT reaction master mix
Component Master mix volume per 15-μL reactiona
100 mM dNTPs (with dTTP) 0.15 μL
MultiScribeTM Reverse Transcriptase, 50 U/μL 1.00 μL
10× Reverse Transcription Buffer 1.50 μL
Rnase Inhibitor, 20 U/μL 0.19 μL
Nuclease-free water 4.16 μL
Total volume 7.00 μL
(B) Performance of reverse transcription
Use the following parameter values to program the thermal cycler:
Step Time Temperature
Hold 30 min 16 °C
Hold 30 min 42 °C
Hold 5 min 85 °C
Hold ∞ 4
(C) Preparation of the qPCR reaction mix
Pipet the following components into each tube:
Component Single reaction
TaqMan Small RNA Assay (x20) 1.00 μL
Product from RT reaction 1.33 μL
TaqMan Universal PCR Master Mix II (x2) 10.00 μL
Nuclease-free water 7.67 μL
Total volume 20.00 μL
(D) Setting up the experiment or plate documentation and running the plate
In real-time PCR system software, create an experiment or plate document on real-time PCR system using the following parameters:
•Run Mode: Standard
•Sample Volume: 20 μL
•Thermal Cycling Conditions:
Enzyme Activation PCR CYCLE (40 cycles)
Step HOLD Denature Anneal/extend
Temperature 95 °C 95 °C 60 °C
Time 10 min 15 s 60 s
aEach 15-μL RT reaction consists of 7 μL master mix, 3 μL of 5× RT primer, and 5 μL RNA sample
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P < 0.001), ΔALT (r = 0.5, P = 0.001), ΔFerritin (r = 0.6,
P < 0.001), and serum miR-122 ratios (r = 0.6, P < 0.001),
respectively. There were also significant and strong associ-
ations between ΔStage and ΔBMI (r = 0.5, P = 0.004),
ΔAST (r = 0.6, P < 0.001), ΔHyaluronic acid (r = 0.5, P =
0.002), and serum miR-122 ratios (r = 0.5, P = 0.002). The
above results pointed to a strong association between
serum miR-122 ratio and changes in histopathological
scores (Fig. 2).
Association of serum miR-122 ratio with changes in other
clinical parameters
We also analyzed the relationship between serum miR-122
ratios and changes in other clinical parameters. There were
significant and strong associations between serum miR-122
ratio and ΔAST (r = 0.7, P < 0.001), ΔALT (r = 0.6, P <
0.001), ΔGGT (r = 0.5, P = 0.003), and ΔFerritin (r = 0.5,
P = 0.001).
Discussion
There is ample evidence to suggest that many epigenetic
mechanisms that are based on histone modifications,
DNA methylation, microRNAs (or miRs), and ubiquiti-
nation, play a pathogenetic role in NAFLD. The miR-122
is significantly downregulated in NAFLD patients. Fur-
thermore, inhibition of miR-122 results in downregulation
of mRNA expression levels of various lipogenic genes and
improvement in liver steatosis [15]. Recent studies that in-
vestigated the utility of circulating microRNA in the as-
sessment of NAFLD found high serum levels of various
microRNAs in patients with NAFLD, and reported strong
association of serum miR-122 levels with histopathological
disease severity [15–18]. Studies by our group also identi-
fied the lack of HCC and/or histopathological severity of
NASH as independent predictors of high levels of serum
miR-122 [21]. However, serum miR-122 levels tended to
be low in fibrosis stage 4, and demonstrated a biphasic
change with progression of fibrosis stage. Furthermore,
long-term follow-up studies of HCC patients showed that
serum miR-122 levels tended to decrease before the pro-
gression of fibrosis stage 4 [21]. Considered together, the
above results suggest that high serum miR-122 levels
could reflect potential future development of HCC, but
not at present, and that low serum miR-122 levels before
progression of fibrosis stage could reflect increased risk of
hepatocarcinogenesis [21]. To minimize the effect of HCC
on serum miR-122 levels, we excluded all patients with
HCC in the present study. Using this approach, we ana-
lyzed the relation between trends in miR-122 and progres-
sion/improvement in NAFLD scores in HCC-free patients
with histopathologically-confirmed NAFLD.
To our knowledge, the present observational study is
the first to demonstrate the association of serum miR-122
with histological features of NAFLD. Serum miR-122
levels at the second biopsy were significantly lower than
those at first biopsy in patients with improvement of
histopathological scores. Furthermore, there were signifi-
cantly strong associations between serum miR-122 ratio
and changes in histopathological scores.
The present study has certain limitations. Our results
showed that patients with improvement and progression
of ballooning scores had significantly low serum miR-122
levels at second biopsy, and that serum miR-122 levels
correlated with improvement in steatosis and fibrosis
Table 3 Distribution of histological scores at the time of the
first and second liver biopsies
Steatosis scores
Scores at second biopsy
0 1 2 3 Total
Scores at first biopsy
1 0 5 3 0 8
2 1 7 11 1 20
3 0 3 1 4 8
Total 1 15 15 5 36
Ballooning scores
Scores at second biopsy
0 1 2 Total
Scores at first biopsy
0 0 2 0 2
1 1 17 3 21
2 3 4 6 13
Total 4 23 9 36
Lobular inflammation scores
Scores at second biopsy
0 1 2 3 Total
Scores at first biopsy
0 0 2 2 0 4
1 0 8 6 0 14
2 2 7 4 0 13
3 0 3 2 0 5
Total 2 20 14 0 36
Stage scores
Scores at second biopsy
0 1 2 3 4 Total
Scores at first biopsy
0 1 4 0 0 0 5
1 1 8 2 2 0 13
2 0 3 2 1 0 6
3 0 1 1 8 1 11
4 0 0 0 1 0 1
Total 2 16 5 12 1 36
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Fig. 1 Logarithmically transformed levels of serum miR-122 at the time of first and second liver biopsies, according to histopathological features
[a Steatosis, b Ballooning, c Lobular inflammation, and d Stage]. In patients with improvement of steatosis, ballooning, and stage scores, serum
miR-122 levels at second biopsy were significantly lower than those at first biopsy
Table 4 Correlation between changes in levels of clinical parameters and histological scores
ΔSteatosis ΔBallooning ΔLobular inflammation ΔStage
r P r P r P r P
ΔAge 0.4 0.011 0.3 0.049 0.3 0.055 0.4 0.026
ΔBody mass index 0.3 0.045 0.3 0.045 0.6 <0.001 0.5 0.004
ΔSerum aspartate aminotransferase 0.4 0.018 0.3 0.126 0.6 <0.001 0.6 <0.001
ΔSerum alanine aminotransferase 0.4 0.018 0.3 0.108 0.5 0.001 0.3 0.054
ΔGamma-glutamyl transpeptidase 0.1 0.555 0.3 0.099 0.3 0.043 0.3 0.044
ΔSerum albumin -0.1 0.748 -0.1 0.393 -0.3 0.110 -0.2 0.165
ΔPlatelet count 0.1 0.740 0.0 0.918 -0.2 0.145 -0.1 0.416
ΔFasting plasma glucose 0.0 0.913 0.2 0.390 0.3 0.102 0.3 0.100
ΔUric acid -0.1 0.671 0.1 0.539 0.2 0.374 0.3 0.089
ΔTotal cholesterol 0.1 0.636 0.3 0.096 0.0 0.992 0.1 0.546
ΔTriglycerides 0.2 0.213 0.1 0.530 0.2 0.195 0.4 0.031
ΔHigh-density lipoprotein cholesterol 0.1 0.738 0.1 0.670 -0.3 0.056 -0.2 0.218
ΔLow-density lipoprotein cholesterol 0.0 0.942 0.2 0.248 0.0 0.855 0.0 0.849
ΔNon high-density lipoprotein cholesterol 0.1 0.675 0.3 0.109 0.1 0.597 0.1 0.385
ΔFerritin 0.3 0.048 0.3 0.063 0.6 <0.001 0.4 0.007
ΔHyaluronic acid 0.2 0.366 0.4 0.036 0.3 0.075 0.5 0.002
Serum miR-122 ratioa 0.5 0.001 0.2 0.226 0.6 <0.001 0.5 0.002
aSerum miR-122 ratio represented the ratio of serum miR-122 level at second biopsy to that at first biopsy
Changes (Δ) in levels of clinical parameters and histopathological scores were calculated by: value at second biopsy minus value at first biopsy
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scores but neither with progression of steatosis nor fibro-
sis scores. These controversial results could be statistically
due to α or β error based on the small number of patients
who showed progression of steatosis. Furthermore, we re-
cently reported that steatosis with grade of fibrosis stage 4
was significantly milder than that of fibrosis stage 0-3
(such as burned-out NASH patients with progression of
fatty changes and inflammatory cell infiltration resolving
in fibrosis [6]). We also showed a tendency for lower
miR-122 serum levels in patients with severe fibrosis stage,
especially fibrosis stage 4 [21]. In the present study, only
one patient showed increase in stage scores from fibrosis
stage 3 at first biopsy to stage 4 at second biopsy, and the
level of serum miRNA-122 decreased from 0.71 fold
change at first biopsy to 0.65 fold change at second biopsy.
Further large-scale longitudinal studies using serial liver
biopsies are needed to determine the complex relationship
between serum miR-122 and histopathological features,
including burned-out NASH.
To our knowledge, there are no studies that used serial
liver biopsies to investigate changes in various clinical
parameters, including serum miR-122, according to the
individual components of NASH (e.g., steatosis, lobular
inflammation, ballooning, and fibrosis stage). Several serial-
biopsy studies have investigated the histopathological
changes and predictive factors of disease progression in
patients with NAFLD [28–32]. Consistent with the re-
cently reported data [33], the present study showed sig-
nificant association between changes in histopathological
features and changes in levels of serum transaminase
(ΔAST and ΔALT). Furthermore, there were significantly
strong associations between serum miR-122 ratio and
changes in other clinical parameters, including serum
transaminases. One limitation of the present study,
probably related to the small number of patients, is that
the priority of these clinical parameters could not be de-
termined. Further large-scale studies should be performed
to identify useful surrogate markers of histopathological
features.
In conclusion, longitudinal examination of serial liver
biopsies showed significant association of serum miR-122
with histopathological features of NAFLD in patients free
of HCC. Further studies of larger number of patients
should be performed to determine the molecular mecha-
nisms of the complex relationship between the impact of
miR-122 on epigenetic risk and pathogenesis of NAFLD.
Conclusions
Longitudinal examination of serial liver biopsies showed
significant association between serum miR-122 and histo-
pathological features of NAFLD patients free of HCC.
Fig. 2 Association between changes in histopathological score [a ΔSteatosis, b ΔBallooning, c ΔLobular inflammation, and d ΔStage] with
logarithmically transformed serum miR-122 ratio. Changes in histopathological scores (Δ) represented the value at second liver biopsy minus
value at first liver biopsy. Serum miR-122 ratio was calculated by (ratio at serum miR-122 level at second liver biopsy/ratio at serum miR-122
level at first liver biopsy). Note the strong associations (r ≥ 0.5) between serum miR-122 ratio and changes in histopathological scores [a ΔSteatosis,
c ΔLobular inflammation, and d ΔStage]
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